Ongoing trials with matrix metalloproteinase inhibitors

Expert Opinion on Investigational Drugs

Volumn 9, Issue 9, 2000, Pages 2167-2177

  Brown, P D ^a  

^a British Biotech Pharmaceuticals Ltd   (United Kingdom)

Author keywords

Cancer; Clinical trial; Matrix metalloproteinases; Protease inhibitor

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; 4 [[[4 (4 CHLOROPHENOXY)PHENYL]SULFONYL]METHYL]TETRAHYDRO 2H PYRAN 4 CARBOHYDROXAMIC ACID; AE 941; CARBOPLATIN; CGS 27023A; CIPEMASTAT; CISPLATIN; GEMCITABINE; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MITOXANTRONE; PACLITAXEL; PRINOMASTAT; REBIMASTAT; SOLIMASTAT; TANOMASTAT; UNCLASSIFIED DRUG;

ARTICLE; BRAIN HEMORRHAGE; BREAST CANCER; CANCER; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESEARCH; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MULTIPLE SCLEROSIS; MUSCULOSKELETAL DISEASE; OSTEOARTHRITIS; PANCREAS CANCER; PATHOGENESIS; PROSTATE CANCER; RESTENOSIS; RETINA MACULA DEGENERATION; RHEUMATOID ARTHRITIS; STOMACH CANCER;

EID: 0033863530     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.9.2167     Document Type: Article

References (39)

1. Matrix metalloproteinases
2. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions
3. Structure determination and analysis of human neutrophil collagenase complexed with a hydoxamate inhibitor
4. Phase I study of i.p. metalloproteinase inhibitor BB94 in patients with malignant ascites
5. Phase I study of intrapleural batimastat (BB-94), an oral matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions
6. Low molecular weight inhibitors in corneal ulceration
7. 1.8-Å crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile
8. Design and therapeutic application of matrix metalloproteinase inhibitors
9. Discovery of CGS 27023A, a non-peptidic, potent and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits
10. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials
11. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers
12. A Phase I study of the matrix metalloproteinase (MMP) inhibitor AG3340 given in single doses to healthy volunteers
13. Comparative pharmacokinetics (PK) of BAY 12-9566, a metalloproteinase (MMP) inhibitor, in healthy volunteers and cancer patients
14. Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo
15. A Phase I pharmacokinetic study of CGS27023A, a matrix metalloproteinase inhibitor
16. Bayer drug casts shadow over MMP inhibitors in cancer
17. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance
18. A comparison between gemcitabine and the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced pancreatic cancer
19. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumour markers in advanced cancer: Selection of a biologically active and tolerable dose for longer-term studies
20. Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor administered orally to patients with advanced lung cancer
21. A Phase I pharmacokinetic evaluation of the matrix metalloproteinase inhibitor AG-3340 in combination with mitoxantrone and prednisone in patients with advanced prostate cancer
22. Phase I study of the matrix metalloproteinase inhibitor Bayer 12-9566
23. A randomised study comparing marimastat to gemcitabine as first line therapy in patients with non-resectable pancreatic cancer
24. A pilot study of the effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer
25. A randomised, double-blind, placebo-controlled study of marimastat in patients with inoperable gastric adenocarcinoma
26. Results of marimastat study 193 in advanced pancreatic cancer
27. Results of marimastat study 131 in glioblastoma multiforme
28. Roche puts arthritis drug on hold
29. Correlation between expression of activated 72-kDa gelatinase and tumour spread in non-small cell lung carcinoma
30. Agouron initiates pivotal trials of oral antiangiogenesis drug AG-3340 for treatment of lung cancer and prostate cancer
31. Agouron announces pilot Phase II clinical trial of its matrix metalloproteinase inhibitor prinomastat in glioblastoma multiforme
32. Aeterna has green light to begin Phase III trial of AE-941/Neovastat in kidney cancer patients in the United States
33. Chiroscience presents update on status of MMPI research
34. CollaGenex reports findings from metastat clinical study
35. Agouron initiates Phase II study of oral anti-angiogenesis drug AG-3340 for treatment of age-related macular degeneration
36. Pilot study of oral marimastat in recurrent colorectal cancer: An evaluation of biological activity by measurement of carcinoembryonic antigen
37. Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: Relationship with levels of circulating CEA
38. Tamoxifen for early breast cancer: An overview of the randomised trials